Zacks Research Issues Pessimistic Outlook for IQVIA Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Analysts at Zacks Research decreased their Q1 2025 earnings per share estimates for shares of IQVIA in a report issued on Thursday, November 21st. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.34 per share for the quarter, down from their prior forecast of $2.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Zacks Research also issued estimates for IQVIA’s Q2 2025 earnings at $2.59 EPS and FY2025 earnings at $10.58 EPS.

Other equities analysts have also issued research reports about the stock. TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Morgan Stanley lowered their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Barclays reduced their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. BTIG Research dropped their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Up 1.1 %

NYSE IQV opened at $204.02 on Monday. The stock has a 50 day moving average price of $221.96 and a 200-day moving average price of $226.98. IQVIA has a one year low of $187.62 and a one year high of $261.73. The company has a market capitalization of $37.03 billion, a P/E ratio of 26.77, a P/E/G ratio of 2.08 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. increased its holdings in IQVIA by 106.4% during the 1st quarter. Advisors Asset Management Inc. now owns 1,298 shares of the medical research company’s stock worth $328,000 after purchasing an additional 669 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of IQVIA by 7.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 886,948 shares of the medical research company’s stock valued at $224,301,000 after acquiring an additional 60,079 shares in the last quarter. Caxton Associates LP purchased a new stake in IQVIA in the first quarter worth about $842,000. B. Riley Wealth Advisors Inc. increased its position in IQVIA by 13.9% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $902,000 after purchasing an additional 436 shares during the period. Finally, Meiji Yasuda Life Insurance Co raised its holdings in shares of IQVIA by 24.0% in the 1st quarter. Meiji Yasuda Life Insurance Co now owns 1,810 shares of the medical research company’s stock valued at $458,000 after purchasing an additional 350 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.